%0 Journal Article
%T Use of Idarucizumab for dabigatran reversal: Emergency department experience in two cases with subdural haematoma
%A Biswadev Mitra
%A Cristina Roman
%A Gail Edwards
%A Rondhir Jithoo
%J Archive of "Trauma Case Reports".
%D 2018
%R 10.1016/j.tcr.2017.12.003
%X Idarucizumab is the first effective humanized monoclonal antibody fragment developed specifically as a reversal agent for dabigatran, a Direct Oral Anticoagulant. Despite recent trials demonstrating reversal of clinically relevant bleeding, there is a paucity of data on use outside the trial setting. This manuscript describes the use of Idarucizumab to reverse dabigatran in two patients presenting to the emergency department of a major tertiary hospital with acute traumatic subdural haematomas (SDH)
%K Idarucizumab
%K Dabigatran
%K Intracranial haemorrhage
%K Wounds and injuries
%K Emergency department
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887121/